The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Encorafenib plus cetuximab in BRAF V600E-mutant mCRC
Scott Kopetz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses clinical implications of BREAKWATER Cohort 3 (NCT04607421) examining first-line encorafenib plus cetuximab with FOLFIRI in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). Results indicate that encorafenib plus cetuximab can be combined with both FOLFIRI and FOLFOX, which were both included in FDA approval. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
